The evaluation of immunological state of patient with stage II-III non-small cell cancer of the lung treated by immunomodulator galavit

Cover Page

Cite item

Abstract

The article presents the results of a clinicoimmunological examination of 61 patients with stage II-III non-small cell cancer of the lung. It has been shown that in the presence of immunomodulating therapy all links of the immunity are being recovered.

About the authors

L Z Velsher

Moskow State University of Medicine and Dentistry

Кафедра онкологии и лучевой терапии; МГМСУ; Moskow State University of Medicine and Dentistry

Z R Gabunia

Moskow State University of Medicine and Dentistry

Кафедра онкологии и лучевой терапии; МГМСУ; Moskow State University of Medicine and Dentistry

L I Korobkova

Moskow State University of Medicine and Dentistry

Кафедра онкологии и лучевой терапии; МГМСУ; Moskow State University of Medicine and Dentistry

D A Platonov

Moskow State University of Medicine and Dentistry

Кафедра онкологии и лучевой терапии; МГМСУ; Moskow State University of Medicine and Dentistry

G P Gens

Moskow State University of Medicine and Dentistry

Кафедра онкологии и лучевой терапии; МГМСУ; Moskow State University of Medicine and Dentistry

T I Grishina

Moskow State University of Medicine and Dentistry

Кафедра клинической иммунологии; МГМСУ; Moskow State University of Medicine and Dentistry

A B Germanov

Semashko Central Clinical Hospital «RZD»

Semashko Central Clinical Hospital «RZD»

M U Bjahov

Semashko Central Clinical Hospital «RZD»

Semashko Central Clinical Hospital «RZD»

V M Argun

Semashko Central Clinical Hospital «RZD»

Semashko Central Clinical Hospital «RZD»

A G Bubnenkov

Semashko Central Clinical Hospital «RZD»

Semashko Central Clinical Hospital «RZD»

References


Copyright (c) 2009 Вельшер Л.З., Габуния З.Р., Коробкова Л.И., Платонов Д.А., Генс Г.П., Гришина Т.И., Германов А.Б., Бяхов М.Ю., Аргун В.М., Бубненков А.Г.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies